De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity: analysis from the HOST-REDUCE-POLYTECH-ACS trial - Lee, H S; Park, K W; Kang, J; Han, J K; Kim, H S (Thromb Haemost, 2022)